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Introduction
Osteoarthritis (OA) is one of the most common musculoskeletal diseases, and its prevalence is rising, particularly since the mid-20th century. In addition, the burden of musculoskeletal diseases increases and is particularly high in Europe (Sebbag et al., 2019) . A recent report of the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 identified OA as the non-communicable disease associated with the most notable increase of total burden and agestandardized disability-adjusted life-years (DALY) rates (+35% and + 4% between 1990 and 2015, respectively) (GBD 2015 DALYs and HALE Collaborators, 2016) . The increased longevity of the most recent generations cannot solely explain this epidemiological observation (Wallace et al., 2017) . Some authors suggest that OA might be considered as a mismatch disease, meaning that OA would be more common today than in the past because genes inherited from previous generations are inadequately or imperfectly adapted to modern environmental conditions (Berenbaum et al., 2018) . Therefore, at any given age, the J o u r n a l P r e -p r o o f 5 prevalence of OA might be higher in modern environments because of higher levels of obesity and chronic metabolic inflammation (metaflammation) favored by physical inactivity, and low-fiber diets with great amounts of processed foods that are rich in sugar and saturated fats. If so, the classical phenotypic approach to OA based on the known risk factors (age, obesity, trauma) and on imaging will likely result in important components of OA pathophysiology being missed, in particular modifiable environmental factors which might be targeted with interventions aimed at improving the development and burden of the disease (Berenbaum, 2019) .
In this context, several sources of data support that microbial dysbiosis, corresponding to an adverse alteration of gut microbiota (GMB) composition and function, is causative of metabolic syndrome and is associated with low-grade inflammation, which are important components of the onset of musculoskeletal diseases. In addition, specific dietary interventions may control low-grade inflammation (Calder et al., 2017; Sanna et al., 2019) . To what extent GMB might represent the missing link between metabolic changes associated with modern environmental conditions and OA pathogenesis and manifestations remains however unclear. Considering the burden of OA and the need to define preventive and therapeutic interventions targeting the modifiable components of OA pathophysiology, a working group was convened by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) to review the potential contribution of GMB to OA. Three main aspects emerged from the review of the topic: first, GMB interacts with many well-recognized risk factors of OA. Second, some observational or intervention studies support the contribution of GMB to OA. Last, interactions between medications and GMB need to be taken into account in OA management.
J o u r n a l P r e -p r o o f 6 2. GMB interactions with risk factors of OA Several risk factors acting together contribute to a complex interplay between mechanical, cellular and biochemical factors leading to the pathogenesis of OA and the individual susceptibility to OA (Figure 1 ) (Hunter and Bierma-Zeinstra, 2019) . Local abnormal loading of joints increases the risk of developing OA. However, non-mechanical factors at the patient level are also involved in this process (Berenbaum, 2013) . It is now clearly established that OA is a low-grade inflammatory condition and that systemic inflammation contributes to the development of OA, and enhances its symptomatic expression, particularly impaired function and pain (Jin et al., 2015) . Important contributors to chronic low-grade inflammation are represented by obesity, metabolic syndrome and a diet rich in saturated fats; the role of the GMB appears to be the missing link between these conditions and OA.
Age and inflammation
The prevalence of OA increases with age. Age-related differences in the GMB composition have been described among young adults, older adults, and centenarians (Claesson et al., 2011; O'Toole and Jeffery, 2015) . In particular, specific alterations of GMB composition were observed in centenarians, notably an increase of opportunistic proinflammatory bacteria generally present in the adult gut ecosystem in low numbers (facultative anaerobes, notably pathobionts), and a marked decrease in symbiotic species with reported anti-inflammatory properties (clostridial clusters such as Faecalibacterium prauznitzii and relatives) . These modifications have been associated with systemic inflammation, since strong correlations exist between plasma levels of pro-inflammatory cytokines, such as IL-6 and IL-8, and the enrichment in bacteria belonging to Proteobacteria phylum or the decrease in the amount of bacteria belonging to Firmicutes phylum (butyrate-producing bacteria, in particular clostridial clusters) (Biagi et al., 2010) . These anti-inflammatory effects may be due, at least J o u r n a l P r e -p r o o f 7 partly, to the secretion by these bacteria of anti-inflammatory peptides belonging to a protein called Microbial Anti-inflammatory Molecule (MAM), or other metabolites, able to block NF-kappa B activation and IL-8 production (Quevrain et al., 2016; Sokol et al., 2008) . These data suggest that the intestinal ecosystem in older subjects contributes to inflammaging . Part of this phenomenon can be assumed to be linked to the aging process, regardless of life-style and dietary habits, since similar patterns were observed in Europe and China (Biagi et al., 2016; Wang et al., 2015) . GMB functional profile analyses confirmed that the age-related changes in GMB are associated with a reduction in genes involved in pathways responsible for the production of short-chain fatty acids (SCFAs) via proteolytic fermentation, as well as an increase in bacterial genes involved in tryptophan metabolism pathways .
2.2.Sex and estrogen
Women are at higher risk of OA, and tend to have more severe OA, particularly after the menopausal age (Srikanth et al., 2005) . The increase in incidence of OA at the time of menopause has led to hypotheses regarding the role of estrogens in OA. Estrogens deprivation may unmask the symptoms of OA by enhancing pain sensitivity (de Kruijf et al., 2016) . The interaction of sex steroids with GMB has been nicely investigated in models of bone loss in hypogonadal mice. These models showed that estrogen deficiency induces the loss of intestine barrier function, leading to endotoxemia and an increase of TNFα-expressing CD4 + T cells, and bone loss (Li et al., 2016b) . In contrast, hypogonadal germ-free mice maintain adequate barrier function following estrogen deficiency and do not experience such bone loss. The reintroduction of gut microbes into germ-free mice reversed the osteoprotection exerted by an absence of microbiota. In addition, sex-steroid deficiency associated bone loss is prevented by probiotics supplementation (Lactobacillus rhamnosus GG) (Iqbal et al., 2016; J o u r n a l P r e -p r o o f 8 2016b). Taken together, these data illustrate that estrogen deficiency may contribute to inflammaging by a microbiota-dependent pathway.
2.3.Obesity
Although the strongest associations between obesity and OA are observed for weightbearing joints, obesity also increases OA risk at non-weight-bearing regions, such as hands (Visser et al., 2015; Yusuf et al., 2010) . Preclinical data support that obesity-related microbial dysbiosis drives the inflammatory process of OA pathogenesis associated with obesity. In various animal models, the severity of adiposity and systemic inflammation increases load-induced cartilage damage (Collins et al., 2015) . Alterations of the GMB composition with chronic antibiotics in mice that spontaneously develop a metabolic syndrome phenotype due to alterations in functions of the gut microbiome, attenuate cartilage damage (Guss et al., 2019) . Restoring a healthy microbial community using the indigestible prebiotic fiber oligofructose in obese mice is associated with a reduction of systemic and knee joint inflammation, a preservation of articular cartilage, and a protection against OA (Schott et al., 2018) . These data suggest that the GMB may contribute to the severity of load-induced OA cartilage pathology and subchondral bone morphology and support the concept of a metabolic phenotype of OA (Szychlinska et al., 2019) .
The GMB might mediate OA via the translocation of microbiota-derived molecules into the systemic circulation. Lipopolysaccharide (LPS) is mainly produced by the gastrointestinal microbiota and its migration from the gut into the circulation contributes to low-grade inflammation. Metabolic endotoxemia involving interaction of gut derived-LPS and Toll-like receptor (TLR) 4 has been recently considered as a common source of low grade inflammation (Boutagy et al., 2016) . The altered clearance of LPS in obesity and metabolic syndrome may contribute as well to the link between these conditions and OA (Huang and environmental factor that affects energy storage and body-fat accumulation. The circadian transcription factor NFIL3 has been identified as an essential molecular link among the GMB, the circadian clock, and host metabolism . Thereby, the regulation of adiposity by GMB might modulate body composition and low-grade chronic inflammation which both contribute to OA pathogenesis and symptoms.
Diet
GMB diversity and functionality are strongly modulated by the host's diet (Mills et al., 2019) .
Postprandial elevation of LPS in the circulation is increased by GMB dysbiosis induced by a high-fat diet. In animal models, diet-induced obesity results in an inflammatory profile promoting the development of metabolic OA (Collins et al., 2016; Collins et al., 2018) . In this regard, a recent study (reported in Table 1) showed that a high-fat/high-sucrose (HFS) diet led to development of knee joint damage in rats that was associated with changes in the metabolic profile in these animals, and that was prevented with prebiotic fiber supplementation and aerobic exercise. In these rats exposed to a HFS diet, prebiotic fiber prevented increases in serum endotoxin and microbial dysbiosis, supporting again the concept that obesity-related metabolic dysregulation and microbial dysbiosis might be strongly linked to the metabolic OA phenotype . In humans, data from the Framingham cohort and the Osteoarthritis Initiative found that intake of dietary fiber was inversely associated with risk of symptomatic OA (Dai et al., 2017a; Dai et al., 2017b) . Further analysis suggested that the association between fiber intake and OA was only in part mediated by BMI and CRP levels (Dai et al., 2018) . Another longitudinal analysis using the Osteoarthritis Initiative database showed that higher adherence to Mediterranean diet was associated with a significantly lower risk of pain worsening and symptomatic knee OA, whilst no significant effect was observed on the incidence of radiographic knee OA. The authors hypothesized that this observation J o u r n a l P r e -p r o o f 11 might be mediated by the anti-inflammatory properties typical of a Mediterranean diet, which is particularly rich in some nutrients that may have a protective effect on OA outcomes, such as fibers and which may lower oxidative stress markers (Veronese et al., 2018) . Fiber-rich diets are the main fermentable sources for SCFAs which contribute to the attenuation of systemic inflammation by inducing regulatory T cells and the control of bone remodeling (Lucas et al., 2018) . SCFAs are also involved in a gut-brain axis which may contribute to pain modulation (Russo et al., 2018) .
Mechanical loading and exercise
Regular physical activity, in particular non-weightbearing exercises, seems to have both preventive and therapeutic benefits for individuals with OA (Mazor et al., 2019) . On the contrary, high-impact sports and regular weightbearing sports may promote OA. Beyond the mechanical effects on cartilage and subchondral bone, the type, intensity and frequency of physical activity may modulate several metabolic pathways via interfering with the GMB.
Exercise might change GMB composition, functional capacity, and metabolites, independently of diet (Monda et al., 2017) . The potential mechanisms involved in response to exercise include the improvement of the Bacteroidetes-Firmicutes ratio, the modification of the profile of bile acids, the increase of SCFAs production, the reduction of LPS effects via suppression of TLR signaling, and the modification of mucosal immunity (Cerda et al., 2016) .
In response to intense exercise, the GMB may control the oxidative stress and inflammatory responses and improve metabolism and energy expenditure (Mach and Fuster-Botella, 2017 ).
These effects may depend on exercise modality and intensity, and on obesity status (Mailing et al., 2019) . Exercise might also be associated with specific diet pattern which may also modulate GMB or its metabolites (Jang et al., 2019) . In animal models, OA induced by destabilization of the medial meniscus is reduced in germ-free mice, suggesting that microbial J o u r n a l P r e -p r o o f 12 dysbiosis could participate to mechanical-loading induced OA (Ulici et al., 2018) . To what extent interventions with exercise in synergy with different diets may rebalance microbial dysbiosis enough to impact OA symptoms or evolution remains to be investigated.
Studies exploring the contribution of GMB to OA

3.1.Observational studies
OA is characterized by a chronic, low-grade inflammation which is mediated primarily by the innate immune system, making it distinct from that observed in rheumatoid arthritis and other autoimmune joint diseases (Robinson et al., 2016) . This concept is supported by the discovery of an increased prevalence of hand OA in obese patients, suggesting that OA in these patients is not solely the result of greater load supported by the joint cartilage and bone, and paving the way to the hypothesis of close links between adipokines, low-grade inflammation, metabolic syndrome and OA (Berenbaum, 2013; Jiang et al., 2016; Reyes et al., 2016) .
The GMB is involved in many physiological functions, including mucosal barrier function, immune system regulation, food digestion (fermentation of undigested nutrients), energy metabolism, and with the production of bioactive agents such as SCFAs, estrogens, and serotonin (Lucas et al., 2018) . The composition of GMB, and its adverse perturbations, may be involved in many chronic diseases known to be associated with musculoskeletal disorders, such as inflammatory bowel diseases, obesity, type 2 diabetes, auto-immune diseases, frailty, malnutrition, and cancer (Bindels et al., 2018; Steves et al., 2016) . Some of these conditions are also classically recognized as risk factors of OA. While several data support the hypothesis that GMB may influence bone homeostasis (D'Amelio and Sassi, 2018; Rizzoli, 2019) , recent observational studies suggest that GMB may also be associated with OA. A large cross-sectional analysis of a population based cohort in UK found that OA was J o u r n a l P r e -p r o o f 13 associated with a large number of GMB features (Jackson et al., 2018) . In particular, the abundance of specific gut microbes (Lentispherea) was negatively associated with prevalence of OA and rheumatoid arthritis (Jackson et al., 2018) . In addition, the presence of bacterial nucleic acids has been identified in synovial fluid and tissue samples of OA lesions. These bacterial nucleic acids were different from those found in samples from patients with rheumatoid arthritis (Zhao et al., 2018) . Taken together, these data support the concept that GMB may influence joint biology. (Lei et al., 2017) . All other studies were performed in animal models of chemical or trauma-induced, or spontaneous OA, including some studies in obese animals. Intervention consisted of supplementation with either probiotics (Korotkyi et al., 2019; Kwon et al., 2018; So et al., 2011) , prebiotics (Rios, 2019; Rios et al., 2019; Schott et al., 2018) or butyrate (Sim et al., 2018) , a SCFA produced by the GMB involved in many metabolic processes. Compared to their respective controls, these interventions decreased the histological changes associated with OA and also modified systemic inflammation profiles. Interestingly, in the two studies using diet-induced obesity, the metabolic profile improvement was linked with dysbiosis correction, strongly supporting J o u r n a l P r e -p r o o f 14 the contribution of the GMB in the pathogenesis of OA in these animal models (Rios, 2019; Rios et al., 2019; Schott et al., 2018) .
Intervention studies
Interactions between medications and GMB in OA management.
It is now established that GMB is a critical determinant of drug metabolism and bioavailability, suggesting that specific GMB composition may influence the response to OA medications ( Figure 2 ) .
First, medications used to decrease OA symptoms affect GMB. In particular opioids alter GMB composition and many of the significant associations seen between GMB and OA overlap with opioid associations (Banerjee et al., 2016) . In addition, NSAID users often take proton pump inhibitors that induce changes of the GMB which may result from the removal of the low pH barrier between the upper and lower gastro-intestinal tract (Jackson et al., 2016) . GMB variation may also influence acetaminophen metabolism and hepatotoxicity Li et al., 2016a) .
Second, glucosamine sulfate and chondroitin sulfate, two symptomatic slow-acting drugs widely used in OA, have limited intestinal absorption and are predominantly utilized by GMB. They may have prebiotic properties (Rani et al., 2019) and therefore exert their therapeutic effects through gut bacterial pathways. A recent systematic review evaluating the evidence for the effects of glucosamine sulfate and chondroitin sulfate on the GMB, showed that chondroitin sulfate supplementation increases the relative abundance of the gut bacterial genus Bacteroides, which may play important roles in regulating the symbiosis in the gut microbial community, as well as host health (Shmagel et al., 2019) . The effect of chondroitin sulfate on OA might also be influenced by the composition of the GMB, in particular its pro-J o u r n a l P r e -p r o o f 15 or anti-inflammatory activity might depend on the presence of specific commensal probiotic bacterial species. The interactions of chondroitin sulfate with an individual GMB spectrum might lead either to compromise or reinforcement of the colonic mucus barrier, and therefore various patterns of in vivo effects in OA . For instance, it has been shown that the degradation profile of chondroitin sulfate differs according to various human microbial consortia, which may contribute to unequal efficacy of chondroitin sulfate on OA symptoms among individuals (Shang et al., 2016) . Similarly, extracts from green-lipped mussels used as a complementary therapy by patients with OA, modulate the GMB composition, with uncertain clinical benefit on OA symptoms (Coulson et al., 2013; Stebbings et al., 2017) . To what extent gut dysbiosis induced by OA medications indirectly increase risk factors of OA such as obesity, metabolic syndrome or loss of muscle mass, remains to be investigated.
Finally, further indirect links might be interesting to consider. An exploratory analysis in the Osteoarthritis Initiative cohort screened 28 medication classes to determine if consistent longterm medication users, compared with nonusers, had different structural and knee pain changes over 24 months. Four medication classes demonstrated a potential signal regarding structural changes, with trends for less disease progression with anti-estrogens, angiotensinconverting enzyme inhibitors, beta-adrenergic blockers, and thyroid agents. Whether these associations are mediated by confounding factors or reflect interactions in metabolic pathways involved in OA pathogenesis remains to be further explored (Driban et al., 2016) . It is interesting to note that interactions with the GMB have been reported with metabolic pathways targeted by these commonly used antihypertensive drugs (angiotensin-converting enzyme inhibitors, β-blockers), and with estrogens and thyroid hormones (Baker et al., 2017; Marques et al., 2017; Virili and Centanni, 2017) .
Research agenda
Although few studies specifically investigated the contribution of GMB to OA, pre-clinical data and observational studies in humans suggest a potential strong relationship between (Table 2 ). This would move the field of OA from symptomatic management to individualized interventions targeting pathogenesis. Risk factors of OA can promote OA either directly, or via modulation of GMB. GMB can also be modulated via other environmental or genetic factors which therefore may indirectly impact OA. GMB-independent risk factors also add to the cascade promoting OA. Potential interactions with GMB have been reported for medications used to decrease OA symptoms, for symptomatic slow-acting drugs used in OA and also for drugs used for non-OA comorbidities. 
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